As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Viridian Therapeutics, Inc. The largest reported stake is Fairmount Funds Management LLC's, at 14.04%. 15 filings are on record since October 27, 2025 (Schedule 13D/A, May 13, 2026).
Sell to companies like Viridian Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 5,687,507 · Sole dispositive: 0 · Shared dispositive: 5,687,507 · SCHEDULE 13G, 2026-08-20
- · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 6,723,788 · Shared voting: 0 · Sole dispositive: 6,723,788 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Kynam Capital Management, LP · Sole voting: 0 · Shared voting: 6,453,877 · Sole dispositive: 0 · Shared dispositive: 6,453,877 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 5,748,380 · Shared voting: 0 · Sole dispositive: 5,748,426 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 3,592,740 · Sole dispositive: 0 · Shared dispositive: 3,592,740 · SCHEDULE 13G/A, 2026-08-14
Viridian Therapeutics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-10-27. 7 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 14.04% | 17,201,800 | SCHEDULE 13D/A, 2026-05-13 | 2026-05-11 |
| Bellevue Group AG | 6.6% | 6,726,144 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Paradigm BioCapital Advisors LP | 6.1% | 6,723,788 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Kynam Capital Management, LP | 5.7% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 5.5% | 6,124,976 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 5.2% | 5,748,426 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Point72 Asset Management, L.P. | 5% | 5,687,507 | SCHEDULE 13G, 2026-08-20 | 2026-08-19 |
| Commodore Capital LP | 3.9% | 3,200,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Deep Track Capital, LP | 3.25% | 3,592,740 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Viridian Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Viridian Therapeutics, Inc. and the records around it.
Viridian Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Watch Viridian Therapeutics, Inc.
Get an email when Viridian Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Viridian Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Viridian Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Viridian Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 6,723,788 | 0 | 6,723,788 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Paradigm BioCapital Advisors GP LLC | 6,723,788 | 0 | 6,723,788 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Senai Asefaw, M.D. | 6,723,788 | 0 | 6,723,788 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Paradigm BioCapital International Fund Ltd. | 5,896,154 | 0 | 5,896,154 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Kynam Capital Management, LP | 0 | 6,453,877 | 0 | 6,453,877 | SCHEDULE 13G/A, 2026-08-14 |
| Kynam Capital Management GP, LLC | 0 | 6,453,877 | 0 | 6,453,877 | SCHEDULE 13G/A, 2026-08-14 |
| Yue Tang | 0 | 6,453,877 | 0 | 6,453,877 | SCHEDULE 13G/A, 2026-08-14 |
| State Street Corporation | 0 | 5,894,254 | 0 | 6,124,976 | SCHEDULE 13G, 2026-08-07 |
| T. Rowe Price Associates, Inc. | 5,748,380 | 0 | 5,748,426 | 0 | SCHEDULE 13G, 2026-08-14 |
| Point72 Asset Management, L.P. | 0 | 5,687,507 | 0 | 5,687,507 | SCHEDULE 13G, 2026-08-20 |
| Point72 Capital Advisors, Inc. | 0 | 5,687,507 | 0 | 5,687,507 | SCHEDULE 13G, 2026-08-20 |
| Steven A. Cohen | 0 | 5,687,507 | 0 | 5,687,507 | SCHEDULE 13G, 2026-08-20 |
| Deep Track Capital, LP | 0 | 3,592,740 | 0 | 3,592,740 | SCHEDULE 13G/A, 2026-08-14 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 3,592,740 | 0 | 3,592,740 | SCHEDULE 13G/A, 2026-08-14 |
| David Kroin | 0 | 3,592,740 | 0 | 3,592,740 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Viridian Therapeutics, Inc. by CUSIP 92790C104 and gives its principal executive office as 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA 02453 (SCHEDULE 13G, 2026-08-20).
What the percentages are based on
See Item 11 on the cover page for each Reporting Person.Paradigm BioCapital Advisors LP, SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Fairmount Funds Management LLC
Item 4 is hereby amended and supplemented as follows: Fund II purchased the shares of Common Stock referenced in Item 3 for investment purposes.Item 4 of the SCHEDULE 13D/A filed 2026-05-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-27 | Fairmount Funds Management LLC | 15.14% | SCHEDULE 13D/A |
| 2025-11-14 | Commodore Capital LP | 3.9% | SCHEDULE 13G/A |
| 2026-02-13 | Deep Track Capital, LP | 2.65% | SCHEDULE 13G/A |
| 2026-02-17 | Kynam Capital Management, LP | 1.54% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-08 | Deep Track Capital, LP | 5.3% | SCHEDULE 13G |
| 2026-05-13 | Fairmount Funds Management LLC | 14.04% | SCHEDULE 13D/A |
| 2026-05-15 | Bellevue Group AG | 6.6% | SCHEDULE 13G |
| 2026-06-26 | Paradigm BioCapital Advisors LP | 5.1% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 5.5% | SCHEDULE 13G |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 5.2% | SCHEDULE 13G |
| 2026-08-14 | Paradigm BioCapital Advisors LP | 6.1% | SCHEDULE 13G/A |
| 2026-08-14 | Deep Track Capital, LP | 3.25% | SCHEDULE 13G/A |
| 2026-08-14 | Kynam Capital Management, LP | 5.7% | SCHEDULE 13G/A |
| 2026-08-20 | Point72 Asset Management, L.P. | 5% | SCHEDULE 13G |
Questions about who owns Viridian Therapeutics, Inc.
Who owns Viridian Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Viridian Therapeutics, Inc.: Fairmount Funds Management LLC (14.04%, Schedule 13D/A, filed 2026-05-13), Bellevue Group AG (6.6%, Schedule 13G, filed 2026-05-15), Paradigm BioCapital Advisors LP (6.1%, Schedule 13G/A, filed 2026-08-14), Kynam Capital Management, LP (5.7%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (5.5%, Schedule 13G, filed 2026-08-07); 2 more are listed above.
Who are the largest shareholders of Viridian Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Viridian Therapeutics, Inc. on this page are Fairmount Funds Management LLC (14.04%), Bellevue Group AG (6.6%) and Paradigm BioCapital Advisors LP (6.1%).
When did Fairmount Funds Management LLC buy into Viridian Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-10-27, reporting 15.14%; its latest, Schedule 13D/A filed 2026-05-13, reports 14.04%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Viridian Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.